Salarius Pharmaceuticals, Inc.

NASDAQ (USD): Salarius Pharmaceuticals, Inc. (SLRX)

Last Price

1.62

Today's Change

+0.07 (4.51%)

Day's Change

1.51 - 1.62

Trading Volume

21,680

Profile
SLRX

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. David J. Arthur M.B.A. Mr. David J. Arthur M.B.A.

Full Time Employees:  2 2

IPO Date:  2015-01-29 2015-01-29

CIK:  0001615219 0001615219

ISIN:  US79400X3052 US79400X3052

CUSIP:  79400X107 79400X107

Beta:  0.93 0.93

Last Dividend:  0.00 0.00

Dcf Diff:  -0.17 -0.17

Dcf:  1.72 1.72

Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Address

2450 Holcombe Boulevard,
Houston, TX 77021, US

832 834 6992

http://www.salariuspharma.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment